nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—muscle cancer	0.45	1	CbGaD
Sulindac—CYP1A1—Dacarbazine—muscle cancer	0.101	0.307	CbGbCtD
Sulindac—PTGS2—Etoposide—muscle cancer	0.0586	0.178	CbGbCtD
Sulindac—PTGS1—Etoposide—muscle cancer	0.0494	0.15	CbGbCtD
Sulindac—CYP1A2—Dacarbazine—muscle cancer	0.0451	0.137	CbGbCtD
Sulindac—SLC22A6—Methotrexate—muscle cancer	0.0286	0.087	CbGbCtD
Sulindac—ALB—Methotrexate—muscle cancer	0.0244	0.0741	CbGbCtD
Sulindac—CYP1A2—Etoposide—muscle cancer	0.0221	0.0671	CbGbCtD
Sulindac—PTGDR2—tendon—muscle cancer	0.00418	0.0658	CbGeAlD
Sulindac—AKR1B1—embryo—muscle cancer	0.00376	0.0592	CbGeAlD
Sulindac—AKR1B1—smooth muscle tissue—muscle cancer	0.00295	0.0465	CbGeAlD
Sulindac—AKR1B1—renal system—muscle cancer	0.00284	0.0448	CbGeAlD
Sulindac—MAPK3—embryo—muscle cancer	0.00272	0.0429	CbGeAlD
Sulindac—AKR1B1—cardiac atrium—muscle cancer	0.00255	0.0401	CbGeAlD
Sulindac—PTGS2—hindlimb—muscle cancer	0.00248	0.0391	CbGeAlD
Sulindac—AKR1B1—tendon—muscle cancer	0.00222	0.035	CbGeAlD
Sulindac—AKR1B1—bone marrow—muscle cancer	0.00215	0.0339	CbGeAlD
Sulindac—MAPK3—smooth muscle tissue—muscle cancer	0.00214	0.0337	CbGeAlD
Sulindac—PTGS2—appendage—muscle cancer	0.00213	0.0336	CbGeAlD
Sulindac—MAPK3—renal system—muscle cancer	0.00206	0.0325	CbGeAlD
Sulindac—AKR1B1—vagina—muscle cancer	0.00206	0.0324	CbGeAlD
Sulindac—AKR1B1—head—muscle cancer	0.0019	0.03	CbGeAlD
Sulindac—MAPK3—cardiac atrium—muscle cancer	0.00185	0.0291	CbGeAlD
Sulindac—AKR1B1—testis—muscle cancer	0.00184	0.029	CbGeAlD
Sulindac—PPARD—tendon—muscle cancer	0.00175	0.0275	CbGeAlD
Sulindac—PPARD—vagina—muscle cancer	0.00162	0.0255	CbGeAlD
Sulindac—MAPK3—tendon—muscle cancer	0.00161	0.0253	CbGeAlD
Sulindac—MAPK3—bone marrow—muscle cancer	0.00156	0.0246	CbGeAlD
Sulindac—PPARD—head—muscle cancer	0.0015	0.0236	CbGeAlD
Sulindac—MAPK3—vagina—muscle cancer	0.00149	0.0235	CbGeAlD
Sulindac—PPARD—testis—muscle cancer	0.00144	0.0228	CbGeAlD
Sulindac—MAPK3—head—muscle cancer	0.00138	0.0217	CbGeAlD
Sulindac—MAPK3—testis—muscle cancer	0.00133	0.021	CbGeAlD
Sulindac—PTGS2—embryo—muscle cancer	0.000707	0.0111	CbGeAlD
Sulindac—CYP1A2—renal system—muscle cancer	0.000646	0.0102	CbGeAlD
Sulindac—CYP1A1—renal system—muscle cancer	0.000637	0.01	CbGeAlD
Sulindac—ALB—testis—muscle cancer	0.000635	0.01	CbGeAlD
Sulindac—PTGS1—smooth muscle tissue—muscle cancer	0.000582	0.00917	CbGeAlD
Sulindac—CYP1A1—cardiac atrium—muscle cancer	0.000571	0.009	CbGeAlD
Sulindac—PTGS1—renal system—muscle cancer	0.00056	0.00882	CbGeAlD
Sulindac—PTGS2—smooth muscle tissue—muscle cancer	0.000556	0.00876	CbGeAlD
Sulindac—PTGS2—renal system—muscle cancer	0.000535	0.00843	CbGeAlD
Sulindac—PTGS1—cardiac atrium—muscle cancer	0.000502	0.0079	CbGeAlD
Sulindac—CYP1A1—vagina—muscle cancer	0.000462	0.00728	CbGeAlD
Sulindac—PTGS1—tendon—muscle cancer	0.000437	0.00689	CbGeAlD
Sulindac—CYP1A1—head—muscle cancer	0.000427	0.00672	CbGeAlD
Sulindac—PTGS2—tendon—muscle cancer	0.000418	0.00658	CbGeAlD
Sulindac—PTGS1—vagina—muscle cancer	0.000406	0.00639	CbGeAlD
Sulindac—PTGS2—bone marrow—muscle cancer	0.000405	0.00638	CbGeAlD
Sulindac—PTGS2—vagina—muscle cancer	0.000388	0.00611	CbGeAlD
Sulindac—PTGS1—head—muscle cancer	0.000375	0.0059	CbGeAlD
Sulindac—PTGS1—testis—muscle cancer	0.000362	0.0057	CbGeAlD
Sulindac—PTGS2—head—muscle cancer	0.000358	0.00564	CbGeAlD
Sulindac—Malaise—Dactinomycin—muscle cancer	0.000355	0.00419	CcSEcCtD
Sulindac—Ecchymosis—Methotrexate—muscle cancer	0.000353	0.00417	CcSEcCtD
Sulindac—Leukopenia—Dactinomycin—muscle cancer	0.000352	0.00416	CcSEcCtD
Sulindac—Gynaecomastia—Methotrexate—muscle cancer	0.000349	0.00412	CcSEcCtD
Sulindac—Agranulocytosis—Etoposide—muscle cancer	0.00034	0.00402	CcSEcCtD
Sulindac—Myalgia—Dactinomycin—muscle cancer	0.000335	0.00396	CcSEcCtD
Sulindac—MAPK3—Signaling Pathways in Glioblastoma—FOXO1—muscle cancer	0.000334	0.00462	CbGpPWpGaD
Sulindac—Hyperkalaemia—Doxorubicin—muscle cancer	0.000332	0.00392	CcSEcCtD
Sulindac—Discomfort—Dactinomycin—muscle cancer	0.000331	0.00391	CcSEcCtD
Sulindac—MAPK3—Kit receptor signaling pathway—KIT—muscle cancer	0.000331	0.00458	CbGpPWpGaD
Sulindac—MAPK3—IGF1R signaling cascade—IGF2—muscle cancer	0.000331	0.00458	CbGpPWpGaD
Sulindac—Anaemia—Vincristine—muscle cancer	0.000325	0.00384	CcSEcCtD
Sulindac—Colitis—Doxorubicin—muscle cancer	0.000324	0.00383	CcSEcCtD
Sulindac—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000323	0.00447	CbGpPWpGaD
Sulindac—Photosensitivity—Methotrexate—muscle cancer	0.000323	0.00381	CcSEcCtD
Sulindac—Oedema—Dactinomycin—muscle cancer	0.000321	0.00379	CcSEcCtD
Sulindac—Aplastic anaemia—Doxorubicin—muscle cancer	0.000317	0.00375	CcSEcCtD
Sulindac—Vertigo—Vincristine—muscle cancer	0.000316	0.00373	CcSEcCtD
Sulindac—Hepatic failure—Methotrexate—muscle cancer	0.000315	0.00372	CcSEcCtD
Sulindac—Leukopenia—Vincristine—muscle cancer	0.000315	0.00372	CcSEcCtD
Sulindac—Thrombocytopenia—Dactinomycin—muscle cancer	0.000315	0.00371	CcSEcCtD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000314	0.00435	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—MED12—muscle cancer	0.000311	0.0043	CbGpPWpGaD
Sulindac—Erythema multiforme—Etoposide—muscle cancer	0.000309	0.00365	CcSEcCtD
Sulindac—Coma—Doxorubicin—muscle cancer	0.000309	0.00365	CcSEcCtD
Sulindac—MAPK3—VEGFR2 mediated cell proliferation—VEGFA—muscle cancer	0.000308	0.00425	CbGpPWpGaD
Sulindac—Anorexia—Dactinomycin—muscle cancer	0.000306	0.00362	CcSEcCtD
Sulindac—Ecchymosis—Doxorubicin—muscle cancer	0.000306	0.00361	CcSEcCtD
Sulindac—Convulsion—Vincristine—muscle cancer	0.000305	0.0036	CcSEcCtD
Sulindac—Flushing—Etoposide—muscle cancer	0.000304	0.00359	CcSEcCtD
Sulindac—Hypertension—Vincristine—muscle cancer	0.000304	0.00359	CcSEcCtD
Sulindac—PPARD—Generic Transcription Pathway—MED12—muscle cancer	0.000301	0.00416	CbGpPWpGaD
Sulindac—Dermatitis exfoliative—Methotrexate—muscle cancer	0.0003	0.00355	CcSEcCtD
Sulindac—Myalgia—Vincristine—muscle cancer	0.000299	0.00354	CcSEcCtD
Sulindac—Visual disturbance—Methotrexate—muscle cancer	0.000299	0.00353	CcSEcCtD
Sulindac—Chills—Etoposide—muscle cancer	0.000294	0.00347	CcSEcCtD
Sulindac—MAPK3—Signaling by SCF-KIT—FOXO4—muscle cancer	0.000293	0.00405	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000293	0.00346	CcSEcCtD
Sulindac—PTGS2—S1P1 pathway—VEGFA—muscle cancer	0.000291	0.00403	CbGpPWpGaD
Sulindac—Alopecia—Etoposide—muscle cancer	0.000289	0.00342	CcSEcCtD
Sulindac—Anaphylactic shock—Vincristine—muscle cancer	0.000287	0.00339	CcSEcCtD
Sulindac—Oedema—Vincristine—muscle cancer	0.000287	0.00339	CcSEcCtD
Sulindac—AKR1B1—Metabolism—ENO2—muscle cancer	0.000283	0.00392	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—CNR1—muscle cancer	0.000283	0.00391	CbGpPWpGaD
Sulindac—Thrombocytopenia—Vincristine—muscle cancer	0.000281	0.00332	CcSEcCtD
Sulindac—MAPK3—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.00028	0.00388	CbGpPWpGaD
Sulindac—Photosensitivity—Doxorubicin—muscle cancer	0.000279	0.0033	CcSEcCtD
Sulindac—Decreased appetite—Dactinomycin—muscle cancer	0.000279	0.0033	CcSEcCtD
Sulindac—Dysgeusia—Etoposide—muscle cancer	0.000279	0.00329	CcSEcCtD
Sulindac—Hyperhidrosis—Vincristine—muscle cancer	0.000277	0.00328	CcSEcCtD
Sulindac—Fatigue—Dactinomycin—muscle cancer	0.000277	0.00327	CcSEcCtD
Sulindac—MAPK3—Signaling by ERBB4—FOXO4—muscle cancer	0.000276	0.00382	CbGpPWpGaD
Sulindac—Vascular purpura—Doxorubicin—muscle cancer	0.000274	0.00324	CcSEcCtD
Sulindac—Anorexia—Vincristine—muscle cancer	0.000274	0.00323	CcSEcCtD
Sulindac—Hepatic failure—Doxorubicin—muscle cancer	0.000273	0.00322	CcSEcCtD
Sulindac—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000271	0.0032	CcSEcCtD
Sulindac—Hypotension—Vincristine—muscle cancer	0.000268	0.00317	CcSEcCtD
Sulindac—Feeling abnormal—Dactinomycin—muscle cancer	0.000265	0.00313	CcSEcCtD
Sulindac—Ill-defined disorder—Etoposide—muscle cancer	0.000264	0.00312	CcSEcCtD
Sulindac—MAPK3—Downstream signal transduction—FOXO4—muscle cancer	0.000263	0.00364	CbGpPWpGaD
Sulindac—Anaemia—Etoposide—muscle cancer	0.000263	0.00311	CcSEcCtD
Sulindac—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000263	0.0031	CcSEcCtD
Sulindac—MAPK3—Signaling by FGFR—FOXO4—muscle cancer	0.000262	0.00363	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—HMGA1—muscle cancer	0.000262	0.00362	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000261	0.00309	CcSEcCtD
Sulindac—MAPK3—Signaling by ERBB2—FOXO4—muscle cancer	0.000261	0.00361	CbGpPWpGaD
Sulindac—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.00026	0.00307	CcSEcCtD
Sulindac—Insomnia—Vincristine—muscle cancer	0.00026	0.00307	CcSEcCtD
Sulindac—MAPK3—DAP12 signaling—FOXO4—muscle cancer	0.00026	0.00359	CbGpPWpGaD
Sulindac—CYP1A2—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000258	0.00357	CbGpPWpGaD
Sulindac—Renal impairment—Doxorubicin—muscle cancer	0.000258	0.00304	CcSEcCtD
Sulindac—Paraesthesia—Vincristine—muscle cancer	0.000258	0.00304	CcSEcCtD
Sulindac—Malaise—Etoposide—muscle cancer	0.000257	0.00303	CcSEcCtD
Sulindac—MAPK3—Oncogene Induced Senescence—TP53—muscle cancer	0.000257	0.00355	CbGpPWpGaD
Sulindac—Vertigo—Etoposide—muscle cancer	0.000256	0.00302	CcSEcCtD
Sulindac—MAPK3—Developmental Biology—MYOG—muscle cancer	0.000256	0.00354	CbGpPWpGaD
Sulindac—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000255	0.00301	CcSEcCtD
Sulindac—Leukopenia—Etoposide—muscle cancer	0.000255	0.00301	CcSEcCtD
Sulindac—Purpura—Doxorubicin—muscle cancer	0.000255	0.00301	CcSEcCtD
Sulindac—Body temperature increased—Dactinomycin—muscle cancer	0.000254	0.003	CcSEcCtD
Sulindac—CYP1A1—PPARA activates gene expression—MED12—muscle cancer	0.000254	0.00351	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000253	0.0035	CbGpPWpGaD
Sulindac—Loss of consciousness—Etoposide—muscle cancer	0.00025	0.00296	CcSEcCtD
Sulindac—Decreased appetite—Vincristine—muscle cancer	0.000249	0.00295	CcSEcCtD
Sulindac—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.000248	0.00344	CbGpPWpGaD
Sulindac—Fatigue—Vincristine—muscle cancer	0.000247	0.00292	CcSEcCtD
Sulindac—Convulsion—Etoposide—muscle cancer	0.000247	0.00292	CcSEcCtD
Sulindac—Hypertension—Etoposide—muscle cancer	0.000246	0.0029	CcSEcCtD
Sulindac—Constipation—Vincristine—muscle cancer	0.000245	0.0029	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000245	0.0029	CcSEcCtD
Sulindac—PTGDR2—Signaling by GPCR—PTCH1—muscle cancer	0.000245	0.00339	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—FOXO4—muscle cancer	0.000244	0.00338	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—FOXO4—muscle cancer	0.000244	0.00338	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.000244	0.00338	CbGpPWpGaD
Sulindac—Chest pain—Etoposide—muscle cancer	0.000243	0.00286	CcSEcCtD
Sulindac—Eosinophilia—Methotrexate—muscle cancer	0.000242	0.00286	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR—FOXO4—muscle cancer	0.000242	0.00335	CbGpPWpGaD
Sulindac—Pancreatitis—Methotrexate—muscle cancer	0.00024	0.00284	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.00024	0.00332	CbGpPWpGaD
Sulindac—Discomfort—Etoposide—muscle cancer	0.00024	0.00283	CcSEcCtD
Sulindac—MAPK3—Signaling by PDGF—FOXO4—muscle cancer	0.000239	0.0033	CbGpPWpGaD
Sulindac—Hypersensitivity—Dactinomycin—muscle cancer	0.000237	0.0028	CcSEcCtD
Sulindac—Gastrointestinal pain—Vincristine—muscle cancer	0.000235	0.00277	CcSEcCtD
Sulindac—Pancytopenia—Methotrexate—muscle cancer	0.000233	0.00275	CcSEcCtD
Sulindac—Anaphylactic shock—Etoposide—muscle cancer	0.000232	0.00275	CcSEcCtD
Sulindac—Asthenia—Dactinomycin—muscle cancer	0.00023	0.00272	CcSEcCtD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.00023	0.00318	CbGpPWpGaD
Sulindac—Dysuria—Methotrexate—muscle cancer	0.000229	0.0027	CcSEcCtD
Sulindac—Neutropenia—Methotrexate—muscle cancer	0.000229	0.0027	CcSEcCtD
Sulindac—PTGDR2—GPCR downstream signaling—CNR1—muscle cancer	0.000228	0.00315	CbGpPWpGaD
Sulindac—Thrombocytopenia—Etoposide—muscle cancer	0.000228	0.00269	CcSEcCtD
Sulindac—Tachycardia—Etoposide—muscle cancer	0.000227	0.00268	CcSEcCtD
Sulindac—Body temperature increased—Vincristine—muscle cancer	0.000227	0.00268	CcSEcCtD
Sulindac—Hyperhidrosis—Etoposide—muscle cancer	0.000225	0.00265	CcSEcCtD
Sulindac—Photosensitivity reaction—Methotrexate—muscle cancer	0.000224	0.00264	CcSEcCtD
Sulindac—AKR1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000222	0.00307	CbGpPWpGaD
Sulindac—Anorexia—Etoposide—muscle cancer	0.000222	0.00262	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000221	0.00261	CcSEcCtD
Sulindac—Diarrhoea—Dactinomycin—muscle cancer	0.00022	0.0026	CcSEcCtD
Sulindac—Pneumonia—Methotrexate—muscle cancer	0.00022	0.00259	CcSEcCtD
Sulindac—Depression—Methotrexate—muscle cancer	0.000218	0.00257	CcSEcCtD
Sulindac—Hypotension—Etoposide—muscle cancer	0.000217	0.00257	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—muscle cancer	0.000217	0.00256	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000216	0.00256	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—muscle cancer	0.000216	0.00256	CcSEcCtD
Sulindac—MAPK3—Signaling by SCF-KIT—FOXO1—muscle cancer	0.000216	0.00299	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.000216	0.00299	CbGpPWpGaD
Sulindac—PTGS1—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000215	0.00297	CbGpPWpGaD
Sulindac—Renal failure—Methotrexate—muscle cancer	0.000215	0.00254	CcSEcCtD
Sulindac—Stomatitis—Methotrexate—muscle cancer	0.000213	0.00251	CcSEcCtD
Sulindac—Conjunctivitis—Methotrexate—muscle cancer	0.000212	0.00251	CcSEcCtD
Sulindac—Hypersensitivity—Vincristine—muscle cancer	0.000211	0.0025	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—muscle cancer	0.00021	0.00248	CcSEcCtD
Sulindac—Sweating—Methotrexate—muscle cancer	0.000209	0.00247	CcSEcCtD
Sulindac—Paraesthesia—Etoposide—muscle cancer	0.000209	0.00247	CcSEcCtD
Sulindac—Haematuria—Methotrexate—muscle cancer	0.000208	0.00246	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—muscle cancer	0.000208	0.00246	CcSEcCtD
Sulindac—Dyspnoea—Etoposide—muscle cancer	0.000207	0.00245	CcSEcCtD
Sulindac—MAPK3—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.000207	0.00286	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—CNR1—muscle cancer	0.000207	0.00286	CbGpPWpGaD
Sulindac—Somnolence—Etoposide—muscle cancer	0.000207	0.00244	CcSEcCtD
Sulindac—MAPK3—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	0.000206	0.00286	CbGpPWpGaD
Sulindac—Epistaxis—Methotrexate—muscle cancer	0.000206	0.00243	CcSEcCtD
Sulindac—Asthenia—Vincristine—muscle cancer	0.000206	0.00243	CcSEcCtD
Sulindac—Vomiting—Dactinomycin—muscle cancer	0.000204	0.00241	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—muscle cancer	0.000204	0.00241	CcSEcCtD
Sulindac—MAPK3—Signaling by ERBB4—FOXO1—muscle cancer	0.000204	0.00282	CbGpPWpGaD
Sulindac—Rash—Dactinomycin—muscle cancer	0.000203	0.00239	CcSEcCtD
Sulindac—Decreased appetite—Etoposide—muscle cancer	0.000202	0.00239	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—muscle cancer	0.000201	0.00238	CcSEcCtD
Sulindac—Fatigue—Etoposide—muscle cancer	0.0002	0.00237	CcSEcCtD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	0.0002	0.00277	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	0.0002	0.00277	CbGpPWpGaD
Sulindac—PPARD—Metabolism—FH—muscle cancer	0.000199	0.00276	CbGpPWpGaD
Sulindac—Constipation—Etoposide—muscle cancer	0.000199	0.00235	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—muscle cancer	0.000198	0.00234	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—muscle cancer	0.000198	0.00234	CcSEcCtD
Sulindac—MAPK3—Cellular responses to stress—HMGA1—muscle cancer	0.000198	0.00274	CbGpPWpGaD
Sulindac—Diarrhoea—Vincristine—muscle cancer	0.000196	0.00232	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—muscle cancer	0.000196	0.00232	CcSEcCtD
Sulindac—MAPK3—Insulin Signaling—FOXO1—muscle cancer	0.000196	0.0027	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—FOXO1—muscle cancer	0.000195	0.00269	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—FOXO1—muscle cancer	0.000194	0.00268	CbGpPWpGaD
Sulindac—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000194	0.00229	CcSEcCtD
Sulindac—MAPK3—Signaling by ERBB2—FOXO1—muscle cancer	0.000193	0.00266	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—FOXO1—muscle cancer	0.000192	0.00265	CbGpPWpGaD
Sulindac—Feeling abnormal—Etoposide—muscle cancer	0.000192	0.00226	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—muscle cancer	0.000191	0.00226	CcSEcCtD
Sulindac—Nausea—Dactinomycin—muscle cancer	0.000191	0.00225	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—muscle cancer	0.00019	0.00225	CcSEcCtD
Sulindac—Gastrointestinal pain—Etoposide—muscle cancer	0.00019	0.00225	CcSEcCtD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—CDKN2A—muscle cancer	0.00019	0.00263	CbGpPWpGaD
Sulindac—Dizziness—Vincristine—muscle cancer	0.00019	0.00224	CcSEcCtD
Sulindac—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—muscle cancer	0.000189	0.00261	CbGpPWpGaD
Sulindac—Visual impairment—Methotrexate—muscle cancer	0.000189	0.00223	CcSEcCtD
Sulindac—MAPK3—Integrins in angiogenesis—VEGFA—muscle cancer	0.000188	0.0026	CbGpPWpGaD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000187	0.00221	CcSEcCtD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000187	0.00259	CbGpPWpGaD
Sulindac—Renal failure—Doxorubicin—muscle cancer	0.000186	0.0022	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—muscle cancer	0.000185	0.00219	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000185	0.00219	CcSEcCtD
Sulindac—Urticaria—Etoposide—muscle cancer	0.000185	0.00218	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—muscle cancer	0.000184	0.00218	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—muscle cancer	0.000184	0.00218	CcSEcCtD
Sulindac—Body temperature increased—Etoposide—muscle cancer	0.000184	0.00217	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—muscle cancer	0.000184	0.00217	CcSEcCtD
Sulindac—MAPK3—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.000183	0.00253	CbGpPWpGaD
Sulindac—Tinnitus—Methotrexate—muscle cancer	0.000183	0.00216	CcSEcCtD
Sulindac—Vomiting—Vincristine—muscle cancer	0.000182	0.00216	CcSEcCtD
Sulindac—Sweating—Doxorubicin—muscle cancer	0.000181	0.00214	CcSEcCtD
Sulindac—Rash—Vincristine—muscle cancer	0.000181	0.00214	CcSEcCtD
Sulindac—Dermatitis—Vincristine—muscle cancer	0.000181	0.00214	CcSEcCtD
Sulindac—MAPK3—DAP12 interactions—FOXO1—muscle cancer	0.00018	0.00249	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.00018	0.00249	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—FOXO1—muscle cancer	0.00018	0.00249	CbGpPWpGaD
Sulindac—Haematuria—Doxorubicin—muscle cancer	0.00018	0.00213	CcSEcCtD
Sulindac—Headache—Vincristine—muscle cancer	0.00018	0.00212	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR—FOXO1—muscle cancer	0.000179	0.00247	CbGpPWpGaD
Sulindac—Epistaxis—Doxorubicin—muscle cancer	0.000178	0.00211	CcSEcCtD
Sulindac—ALB—Platelet degranulation—IGF2—muscle cancer	0.000178	0.00246	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.000177	0.00245	CbGpPWpGaD
Sulindac—MAPK3—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—muscle cancer	0.000177	0.00244	CbGpPWpGaD
Sulindac—Agranulocytosis—Doxorubicin—muscle cancer	0.000176	0.00208	CcSEcCtD
Sulindac—MAPK3—Signaling by PDGF—FOXO1—muscle cancer	0.000176	0.00244	CbGpPWpGaD
Sulindac—Chills—Methotrexate—muscle cancer	0.000176	0.00208	CcSEcCtD
Sulindac—MAPK3—Hemostasis—ANGPT2—muscle cancer	0.000174	0.00241	CbGpPWpGaD
Sulindac—Alopecia—Methotrexate—muscle cancer	0.000173	0.00205	CcSEcCtD
Sulindac—Hypersensitivity—Etoposide—muscle cancer	0.000171	0.00202	CcSEcCtD
Sulindac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000171	0.00237	CbGpPWpGaD
Sulindac—Nausea—Vincristine—muscle cancer	0.00017	0.00201	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—muscle cancer	0.00017	0.002	CcSEcCtD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.00017	0.00235	CbGpPWpGaD
Sulindac—MAPK3—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—muscle cancer	0.000169	0.00234	CbGpPWpGaD
Sulindac—CYP1A1—Tryptophan metabolism—MDM2—muscle cancer	0.000168	0.00232	CbGpPWpGaD
Sulindac—Dysgeusia—Methotrexate—muscle cancer	0.000167	0.00197	CcSEcCtD
Sulindac—Asthenia—Etoposide—muscle cancer	0.000167	0.00197	CcSEcCtD
Sulindac—MAPK3—Signaling by NGF—FOXO4—muscle cancer	0.000166	0.0023	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—KIT—muscle cancer	0.000165	0.00228	CbGpPWpGaD
Sulindac—Pruritus—Etoposide—muscle cancer	0.000164	0.00194	CcSEcCtD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000164	0.00227	CbGpPWpGaD
Sulindac—Visual impairment—Doxorubicin—muscle cancer	0.000164	0.00193	CcSEcCtD
Sulindac—MAPK3—M Phase—BUB1B—muscle cancer	0.000162	0.00224	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.000162	0.00224	CbGpPWpGaD
Sulindac—Vision blurred—Methotrexate—muscle cancer	0.000161	0.0019	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—muscle cancer	0.00016	0.0019	CcSEcCtD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.00016	0.00221	CbGpPWpGaD
Sulindac—Diarrhoea—Etoposide—muscle cancer	0.000159	0.00188	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—muscle cancer	0.000158	0.00187	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—muscle cancer	0.000158	0.00187	CcSEcCtD
Sulindac—MAPK3—Developmental Biology—MYOD1—muscle cancer	0.000158	0.00219	CbGpPWpGaD
Sulindac—Anaemia—Methotrexate—muscle cancer	0.000158	0.00186	CcSEcCtD
Sulindac—MAPK3—Downstream signaling of activated FGFR—KIT—muscle cancer	0.000158	0.00218	CbGpPWpGaD
Sulindac—Flushing—Doxorubicin—muscle cancer	0.000158	0.00186	CcSEcCtD
Sulindac—MAPK3—Signaling by ERBB4—KIT—muscle cancer	0.000155	0.00215	CbGpPWpGaD
Sulindac—Malaise—Methotrexate—muscle cancer	0.000154	0.00182	CcSEcCtD
Sulindac—Dizziness—Etoposide—muscle cancer	0.000154	0.00182	CcSEcCtD
Sulindac—Vertigo—Methotrexate—muscle cancer	0.000153	0.00181	CcSEcCtD
Sulindac—MAPK3—Oxidative Stress Induced Senescence—CDKN2A—muscle cancer	0.000153	0.00212	CbGpPWpGaD
Sulindac—Leukopenia—Methotrexate—muscle cancer	0.000153	0.0018	CcSEcCtD
Sulindac—Chills—Doxorubicin—muscle cancer	0.000152	0.0018	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—muscle cancer	0.000152	0.00179	CcSEcCtD
Sulindac—CYP1A1—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000151	0.00209	CbGpPWpGaD
Sulindac—Alopecia—Doxorubicin—muscle cancer	0.00015	0.00177	CcSEcCtD
Sulindac—MAPK3—Mitotic M-M/G1 phases—BUB1B—muscle cancer	0.000149	0.00206	CbGpPWpGaD
Sulindac—MAPK3—Oxidative Stress Induced Senescence—MDM2—muscle cancer	0.000149	0.00206	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—KIT—muscle cancer	0.000148	0.00205	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—KIT—muscle cancer	0.000148	0.00205	CbGpPWpGaD
Sulindac—Convulsion—Methotrexate—muscle cancer	0.000148	0.00175	CcSEcCtD
Sulindac—Vomiting—Etoposide—muscle cancer	0.000148	0.00175	CcSEcCtD
Sulindac—MAPK3—Signaling by FGFR—KIT—muscle cancer	0.000147	0.00204	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—KIT—muscle cancer	0.000147	0.00203	CbGpPWpGaD
Sulindac—Rash—Etoposide—muscle cancer	0.000147	0.00173	CcSEcCtD
Sulindac—Dermatitis—Etoposide—muscle cancer	0.000146	0.00173	CcSEcCtD
Sulindac—MAPK3—DAP12 signaling—KIT—muscle cancer	0.000146	0.00202	CbGpPWpGaD
Sulindac—Headache—Etoposide—muscle cancer	0.000146	0.00172	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—muscle cancer	0.000146	0.00172	CcSEcCtD
Sulindac—Chest pain—Methotrexate—muscle cancer	0.000145	0.00172	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—muscle cancer	0.000145	0.00172	CcSEcCtD
Sulindac—Myalgia—Methotrexate—muscle cancer	0.000145	0.00172	CcSEcCtD
Sulindac—Tension—Doxorubicin—muscle cancer	0.000145	0.00171	CcSEcCtD
Sulindac—PPARD—Gene Expression—MED12—muscle cancer	0.000145	0.002	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PTCH1—muscle cancer	0.000145	0.002	CbGpPWpGaD
Sulindac—Dysgeusia—Doxorubicin—muscle cancer	0.000145	0.00171	CcSEcCtD
Sulindac—MAPK3—Developmental Biology—MED12—muscle cancer	0.000145	0.002	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—PTGS2—muscle cancer	0.000144	0.002	CbGpPWpGaD
Sulindac—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000144	0.00199	CbGpPWpGaD
Sulindac—Discomfort—Methotrexate—muscle cancer	0.000144	0.0017	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—muscle cancer	0.000143	0.00169	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—muscle cancer	0.000139	0.00164	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—muscle cancer	0.000139	0.00164	CcSEcCtD
Sulindac—MAPK3—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.000138	0.00191	CbGpPWpGaD
Sulindac—Nausea—Etoposide—muscle cancer	0.000138	0.00163	CcSEcCtD
Sulindac—MAPK3—Signaling by FGFR in disease—KIT—muscle cancer	0.000137	0.0019	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—KIT—muscle cancer	0.000137	0.0019	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000137	0.0019	CbGpPWpGaD
Sulindac—Ill-defined disorder—Doxorubicin—muscle cancer	0.000137	0.00162	CcSEcCtD
Sulindac—PTGS1—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000137	0.00189	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000137	0.00189	CbGpPWpGaD
Sulindac—Anaemia—Doxorubicin—muscle cancer	0.000137	0.00161	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—muscle cancer	0.000136	0.00161	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR—KIT—muscle cancer	0.000136	0.00188	CbGpPWpGaD
Sulindac—MAPK3—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	0.000135	0.00187	CbGpPWpGaD
Sulindac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000135	0.00187	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000135	0.00187	CbGpPWpGaD
Sulindac—Hyperhidrosis—Methotrexate—muscle cancer	0.000135	0.00159	CcSEcCtD
Sulindac—MAPK3—Signaling by PDGF—KIT—muscle cancer	0.000134	0.00186	CbGpPWpGaD
Sulindac—Malaise—Doxorubicin—muscle cancer	0.000133	0.00157	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—muscle cancer	0.000133	0.00157	CcSEcCtD
Sulindac—Anorexia—Methotrexate—muscle cancer	0.000133	0.00157	CcSEcCtD
Sulindac—Syncope—Doxorubicin—muscle cancer	0.000132	0.00156	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—muscle cancer	0.000132	0.00156	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—muscle cancer	0.000131	0.00154	CcSEcCtD
Sulindac—Hypotension—Methotrexate—muscle cancer	0.00013	0.00154	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—muscle cancer	0.00013	0.00153	CcSEcCtD
Sulindac—MAPK3—Signaling by SCF-KIT—MDM2—muscle cancer	0.00013	0.0018	CbGpPWpGaD
Sulindac—Convulsion—Doxorubicin—muscle cancer	0.000128	0.00151	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—muscle cancer	0.000128	0.00151	CcSEcCtD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000127	0.00176	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000127	0.0015	CcSEcCtD
Sulindac—Insomnia—Methotrexate—muscle cancer	0.000126	0.00149	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—muscle cancer	0.000126	0.00149	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—muscle cancer	0.000126	0.00149	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—muscle cancer	0.000126	0.00149	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—muscle cancer	0.000125	0.00148	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—FOXO4—muscle cancer	0.000124	0.00172	CbGpPWpGaD
Sulindac—Discomfort—Doxorubicin—muscle cancer	0.000124	0.00147	CcSEcCtD
Sulindac—MAPK3—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000124	0.00172	CbGpPWpGaD
Sulindac—Dyspnoea—Methotrexate—muscle cancer	0.000124	0.00147	CcSEcCtD
Sulindac—Somnolence—Methotrexate—muscle cancer	0.000124	0.00146	CcSEcCtD
Sulindac—MAPK3—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000123	0.0017	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—FOXO1—muscle cancer	0.000123	0.0017	CbGpPWpGaD
Sulindac—Dyspepsia—Methotrexate—muscle cancer	0.000123	0.00145	CcSEcCtD
Sulindac—MAPK3—Signaling by ERBB4—MDM2—muscle cancer	0.000122	0.00169	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CNR1—muscle cancer	0.000122	0.00169	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000122	0.00168	CbGpPWpGaD
Sulindac—Decreased appetite—Methotrexate—muscle cancer	0.000121	0.00143	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—muscle cancer	0.000121	0.00142	CcSEcCtD
Sulindac—Oedema—Doxorubicin—muscle cancer	0.000121	0.00142	CcSEcCtD
Sulindac—PTGS2—C-MYB transcription factor network—CDKN2A—muscle cancer	0.00012	0.00167	CbGpPWpGaD
Sulindac—Fatigue—Methotrexate—muscle cancer	0.00012	0.00142	CcSEcCtD
Sulindac—Shock—Doxorubicin—muscle cancer	0.000119	0.0014	CcSEcCtD
Sulindac—MAPK3—Alzheimers Disease—TP53—muscle cancer	0.000118	0.00164	CbGpPWpGaD
Sulindac—Thrombocytopenia—Doxorubicin—muscle cancer	0.000118	0.00139	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—muscle cancer	0.000118	0.00139	CcSEcCtD
Sulindac—MAPK3—Downstream signal transduction—MDM2—muscle cancer	0.000117	0.00161	CbGpPWpGaD
Sulindac—Hyperhidrosis—Doxorubicin—muscle cancer	0.000117	0.00138	CcSEcCtD
Sulindac—MAPK3—Signaling by FGFR—MDM2—muscle cancer	0.000116	0.00161	CbGpPWpGaD
Sulindac—MAPK3—Signaling by VEGF—VEGFA—muscle cancer	0.000116	0.00161	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—MDM2—muscle cancer	0.000116	0.0016	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—MDM2—muscle cancer	0.000115	0.00159	CbGpPWpGaD
Sulindac—Anorexia—Doxorubicin—muscle cancer	0.000115	0.00136	CcSEcCtD
Sulindac—MAPK3—Signaling Pathways in Glioblastoma—TP53—muscle cancer	0.000115	0.00159	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—TP53—muscle cancer	0.000115	0.00159	CbGpPWpGaD
Sulindac—Feeling abnormal—Methotrexate—muscle cancer	0.000115	0.00136	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—muscle cancer	0.000114	0.00134	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—muscle cancer	0.000113	0.00133	CcSEcCtD
Sulindac—PPARD—Metabolism—MED12—muscle cancer	0.000113	0.00156	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—BUB1B—muscle cancer	0.000111	0.00154	CbGpPWpGaD
Sulindac—Urticaria—Methotrexate—muscle cancer	0.000111	0.00131	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—muscle cancer	0.00011	0.0013	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00011	0.0013	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—muscle cancer	0.000109	0.00129	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—muscle cancer	0.000108	0.00128	CcSEcCtD
Sulindac—MAPK3—Signaling by FGFR in disease—MDM2—muscle cancer	0.000108	0.0015	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—MDM2—muscle cancer	0.000108	0.0015	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000108	0.0015	CbGpPWpGaD
Sulindac—Dyspnoea—Doxorubicin—muscle cancer	0.000108	0.00127	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR—MDM2—muscle cancer	0.000107	0.00148	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—CDKN2A—muscle cancer	0.000107	0.00148	CbGpPWpGaD
Sulindac—Somnolence—Doxorubicin—muscle cancer	0.000107	0.00127	CcSEcCtD
Sulindac—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	0.000107	0.00148	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000106	0.00147	CbGpPWpGaD
Sulindac—Dyspepsia—Doxorubicin—muscle cancer	0.000106	0.00125	CcSEcCtD
Sulindac—MAPK3—Signaling by PDGF—MDM2—muscle cancer	0.000106	0.00146	CbGpPWpGaD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—TP53—muscle cancer	0.000106	0.00146	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KIDINS220—muscle cancer	0.000106	0.00146	CbGpPWpGaD
Sulindac—Decreased appetite—Doxorubicin—muscle cancer	0.000105	0.00124	CcSEcCtD
Sulindac—MAPK3—Cellular Senescence—MDM2—muscle cancer	0.000104	0.00144	CbGpPWpGaD
Sulindac—Fatigue—Doxorubicin—muscle cancer	0.000104	0.00123	CcSEcCtD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.000103	0.00143	CbGpPWpGaD
Sulindac—Constipation—Doxorubicin—muscle cancer	0.000103	0.00122	CcSEcCtD
Sulindac—PPARD—Metabolism—ENO2—muscle cancer	0.000103	0.00142	CbGpPWpGaD
Sulindac—Hypersensitivity—Methotrexate—muscle cancer	0.000103	0.00121	CcSEcCtD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000102	0.00141	CbGpPWpGaD
Sulindac—Asthenia—Methotrexate—muscle cancer	9.99e-05	0.00118	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—IGF2—muscle cancer	9.99e-05	0.00138	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—BUB1B—muscle cancer	9.94e-05	0.00138	CbGpPWpGaD
Sulindac—Feeling abnormal—Doxorubicin—muscle cancer	9.94e-05	0.00117	CcSEcCtD
Sulindac—AKR1B1—Metabolism—PTGS2—muscle cancer	9.87e-05	0.00137	CbGpPWpGaD
Sulindac—Gastrointestinal pain—Doxorubicin—muscle cancer	9.86e-05	0.00116	CcSEcCtD
Sulindac—Pruritus—Methotrexate—muscle cancer	9.85e-05	0.00116	CcSEcCtD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	9.82e-05	0.00136	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9.67e-05	0.00134	CbGpPWpGaD
Sulindac—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	9.65e-05	0.00134	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	9.58e-05	0.00133	CbGpPWpGaD
Sulindac—Urticaria—Doxorubicin—muscle cancer	9.58e-05	0.00113	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—muscle cancer	9.53e-05	0.00113	CcSEcCtD
Sulindac—Diarrhoea—Methotrexate—muscle cancer	9.53e-05	0.00113	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—FOXO4—muscle cancer	9.49e-05	0.00131	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—KIT—muscle cancer	9.36e-05	0.00129	CbGpPWpGaD
Sulindac—Dizziness—Methotrexate—muscle cancer	9.21e-05	0.00109	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—FOXO1—muscle cancer	9.19e-05	0.00127	CbGpPWpGaD
Sulindac—Hypersensitivity—Doxorubicin—muscle cancer	8.88e-05	0.00105	CcSEcCtD
Sulindac—Vomiting—Methotrexate—muscle cancer	8.85e-05	0.00105	CcSEcCtD
Sulindac—Rash—Methotrexate—muscle cancer	8.78e-05	0.00104	CcSEcCtD
Sulindac—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	8.78e-05	0.00121	CbGpPWpGaD
Sulindac—Dermatitis—Methotrexate—muscle cancer	8.77e-05	0.00104	CcSEcCtD
Sulindac—Headache—Methotrexate—muscle cancer	8.72e-05	0.00103	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—muscle cancer	8.65e-05	0.00102	CcSEcCtD
Sulindac—MAPK3—Spinal Cord Injury—TP53—muscle cancer	8.59e-05	0.00119	CbGpPWpGaD
Sulindac—Pruritus—Doxorubicin—muscle cancer	8.53e-05	0.00101	CcSEcCtD
Sulindac—MAPK3—Oxidative Stress Induced Senescence—TP53—muscle cancer	8.53e-05	0.00118	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IGF2—muscle cancer	8.46e-05	0.00117	CbGpPWpGaD
Sulindac—ALB—Hemostasis—ANGPT2—muscle cancer	8.37e-05	0.00116	CbGpPWpGaD
Sulindac—Nausea—Methotrexate—muscle cancer	8.27e-05	0.000977	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—muscle cancer	8.25e-05	0.000974	CcSEcCtD
Sulindac—MAPK3—Immune System—CD34—muscle cancer	8.13e-05	0.00112	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	8.13e-05	0.00112	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—CDKN2A—muscle cancer	8.1e-05	0.00112	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.03e-05	0.00111	CbGpPWpGaD
Sulindac—Dizziness—Doxorubicin—muscle cancer	7.97e-05	0.000942	CcSEcCtD
Sulindac—MAPK3—Developmental Biology—FOXO1—muscle cancer	7.93e-05	0.0011	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	7.89e-05	0.00109	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—MDM2—muscle cancer	7.86e-05	0.00109	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	7.73e-05	0.00107	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.68e-05	0.00106	CbGpPWpGaD
Sulindac—Vomiting—Doxorubicin—muscle cancer	7.67e-05	0.000906	CcSEcCtD
Sulindac—PTGS1—Metabolism—FH—muscle cancer	7.62e-05	0.00105	CbGpPWpGaD
Sulindac—Rash—Doxorubicin—muscle cancer	7.6e-05	0.000898	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—muscle cancer	7.6e-05	0.000897	CcSEcCtD
Sulindac—Headache—Doxorubicin—muscle cancer	7.55e-05	0.000892	CcSEcCtD
Sulindac—ALB—Platelet degranulation—VEGFA—muscle cancer	7.46e-05	0.00103	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MED12—muscle cancer	7.39e-05	0.00102	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—MDM2—muscle cancer	7.37e-05	0.00102	CbGpPWpGaD
Sulindac—Nausea—Doxorubicin—muscle cancer	7.16e-05	0.000846	CcSEcCtD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	7.11e-05	0.000984	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PTCH1—muscle cancer	7.03e-05	0.000973	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—FOXO1—muscle cancer	7.01e-05	0.000969	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KIT—muscle cancer	7.01e-05	0.000969	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	6.88e-05	0.000952	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	6.81e-05	0.000943	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—muscle cancer	6.58e-05	0.00091	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—muscle cancer	6.47e-05	0.000896	CbGpPWpGaD
Sulindac—MAPK3—Disease—ENO2—muscle cancer	6.26e-05	0.000866	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	6.21e-05	0.000859	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	6.06e-05	0.000838	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—FH—muscle cancer	6.05e-05	0.000837	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—VEGFA—muscle cancer	5.97e-05	0.000826	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—muscle cancer	5.97e-05	0.000826	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CNR1—muscle cancer	5.94e-05	0.000821	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.84e-05	0.000808	CbGpPWpGaD
Sulindac—MAPK3—Disease—HMGA1—muscle cancer	5.69e-05	0.000787	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FOXO4—muscle cancer	5.53e-05	0.000764	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MDM2—muscle cancer	5.52e-05	0.000763	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—FH—muscle cancer	5.37e-05	0.000743	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KIT—muscle cancer	5.34e-05	0.000739	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—muscle cancer	5.11e-05	0.000707	CbGpPWpGaD
Sulindac—MAPK3—Disease—FOXO4—muscle cancer	5.1e-05	0.000706	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CDKN2A—muscle cancer	5.08e-05	0.000703	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—VEGFA—muscle cancer	5.07e-05	0.000701	CbGpPWpGaD
Sulindac—ALB—Metabolism—FH—muscle cancer	4.9e-05	0.000677	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.6e-05	0.000636	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CDKN2A—muscle cancer	4.54e-05	0.000629	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—muscle cancer	4.51e-05	0.000624	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MDM2—muscle cancer	4.41e-05	0.00061	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.34e-05	0.000601	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—MED12—muscle cancer	4.31e-05	0.000596	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—MDM2—muscle cancer	4.2e-05	0.000582	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—VEGFA—muscle cancer	4.19e-05	0.00058	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTCH1—muscle cancer	4.15e-05	0.000575	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FOXO1—muscle cancer	4.08e-05	0.000565	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IGF2—muscle cancer	4.07e-05	0.000563	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ENO2—muscle cancer	3.93e-05	0.000543	CbGpPWpGaD
Sulindac—MAPK3—Disease—FOXO1—muscle cancer	3.77e-05	0.000521	CbGpPWpGaD
Sulindac—PTGS2—Disease—ENO2—muscle cancer	3.72e-05	0.000515	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—muscle cancer	3.62e-05	0.0005	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—muscle cancer	3.58e-05	0.000495	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FOXO4—muscle cancer	3.57e-05	0.000494	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—muscle cancer	3.55e-05	0.000491	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CNR1—muscle cancer	3.51e-05	0.000485	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.47e-05	0.000481	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—FH—muscle cancer	3.42e-05	0.000474	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MED12—muscle cancer	3.42e-05	0.000473	CbGpPWpGaD
Sulindac—PTGS2—Disease—HMGA1—muscle cancer	3.38e-05	0.000468	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	3.31e-05	0.000458	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—muscle cancer	3.17e-05	0.000438	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ENO2—muscle cancer	3.12e-05	0.000431	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KIT—muscle cancer	3.11e-05	0.00043	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.07e-05	0.000425	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MED12—muscle cancer	3.03e-05	0.00042	CbGpPWpGaD
Sulindac—PTGS2—Disease—FOXO4—muscle cancer	3.03e-05	0.00042	CbGpPWpGaD
Sulindac—MAPK3—Disease—KIT—muscle cancer	2.87e-05	0.000397	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF2—muscle cancer	2.87e-05	0.000397	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ENO2—muscle cancer	2.77e-05	0.000383	CbGpPWpGaD
Sulindac—ALB—Metabolism—MED12—muscle cancer	2.77e-05	0.000383	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—muscle cancer	2.68e-05	0.000371	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FOXO1—muscle cancer	2.64e-05	0.000365	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—muscle cancer	2.53e-05	0.00035	CbGpPWpGaD
Sulindac—ALB—Metabolism—ENO2—muscle cancer	2.52e-05	0.000349	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MDM2—muscle cancer	2.45e-05	0.000339	CbGpPWpGaD
Sulindac—MAPK3—Disease—MDM2—muscle cancer	2.26e-05	0.000313	CbGpPWpGaD
Sulindac—PTGS2—Disease—FOXO1—muscle cancer	2.24e-05	0.00031	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—muscle cancer	2.18e-05	0.000302	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.16e-05	0.000299	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KIT—muscle cancer	2.01e-05	0.000278	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.97e-05	0.000273	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MED12—muscle cancer	1.93e-05	0.000268	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ENO2—muscle cancer	1.76e-05	0.000244	CbGpPWpGaD
Sulindac—PTGS2—Disease—KIT—muscle cancer	1.71e-05	0.000236	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—muscle cancer	1.71e-05	0.000236	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MDM2—muscle cancer	1.58e-05	0.000219	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.38e-05	0.000191	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—muscle cancer	1.37e-05	0.000189	CbGpPWpGaD
Sulindac—PTGS2—Disease—MDM2—muscle cancer	1.34e-05	0.000186	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—muscle cancer	1.29e-05	0.000178	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—muscle cancer	1.2e-05	0.000166	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—muscle cancer	9.63e-06	0.000133	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—muscle cancer	9.08e-06	0.000126	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—muscle cancer	8.78e-06	0.000122	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—muscle cancer	6.14e-06	8.5e-05	CbGpPWpGaD
